Bradley Canino
Stock Analyst at Stifel
(1.50)
# 3,549
Out of 5,115 analysts
82
Total ratings
32.88%
Success rate
-5.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Buy | $46 → $38 | $13.71 | +177.17% | 4 | Dec 2, 2025 | |
| SNDX Syndax Pharmaceuticals | Reinstates: Buy | $44 | $20.31 | +116.64% | 7 | Sep 10, 2025 | |
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $2.49 | +502.41% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $1.74 | -13.79% | 8 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $23 → $19 | $11.96 | +58.86% | 2 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $7.66 | +200.26% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $13.38 | +281.17% | 6 | Feb 12, 2025 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $8.12 | +133.99% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $109.42 | -61.62% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $14.48 | +176.24% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $102.97 | +31.11% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $10.26 | +94.93% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.45 | +589.66% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $2.43 | +311.52% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $1.90 | +636.84% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $72.69 | -24.34% | 4 | Feb 23, 2024 |
Janux Therapeutics
Dec 2, 2025
Maintains: Buy
Price Target: $46 → $38
Current: $13.71
Upside: +177.17%
Syndax Pharmaceuticals
Sep 10, 2025
Reinstates: Buy
Price Target: $44
Current: $20.31
Upside: +116.64%
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $2.49
Upside: +502.41%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $1.74
Upside: -13.79%
Cullinan Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $19
Current: $11.96
Upside: +58.86%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $7.66
Upside: +200.26%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $13.38
Upside: +281.17%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $8.12
Upside: +133.99%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $109.42
Upside: -61.62%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $14.48
Upside: +176.24%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $102.97
Upside: +31.11%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $10.26
Upside: +94.93%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $1.45
Upside: +589.66%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $2.43
Upside: +311.52%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $1.90
Upside: +636.84%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $72.69
Upside: -24.34%